Recombinant Mouse C-C chemokine receptor type 8 (Ccr8)

What is mouse CCR8 and how does it differ from human CCR8?

Mouse CCR8 (also known as CD198) is a 41-43 kDa G-protein coupled receptor belonging to the beta-chemokine receptor family. It functions primarily in immune cell trafficking and inflammatory responses. The mouse variant is a 353 amino acid 7-transmembrane protein containing a 33 amino acid N-terminal extracellular domain and a 50 amino acid C-terminal cytoplasmic tail . Structurally, mouse CCR8 shares limited sequence homology with its human counterpart, with only 64% amino acid identity in the N-terminal domain (amino acids 1-33) and certain internal sequences (amino acids 92-105) . This moderate conservation suggests functional similarities but requires caution when extrapolating research findings between species. Researchers should consider these interspecies differences when designing experiments and interpreting results from mouse models for potential human applications.

Which cell types express mouse CCR8 and how can expression patterns be validated?

Mouse CCR8 demonstrates a defined expression pattern across multiple immune and non-immune cell types. It is predominantly expressed on vascular smooth muscle cells, monocytes, eosinophils, peritoneal macrophages, thymocytes, CD8+ T cells, Langerhans cells, and certain neuronal populations . Particularly high expression is observed in regulatory T cells (Tregs) within tumor microenvironments, making it a valuable marker for tumor-infiltrating Tregs .

For expression validation, researchers should employ multiple complementary techniques:

• Flow cytometry using validated anti-CCR8 antibodies such as Alexa Fluor 750-conjugated antibodies

• Quantitative RT-PCR targeting CCR8 mRNA

• Western blotting (noting that posttranslational modifications may cause anomalous migration patterns)

• Immunohistochemistry in tissue sections with appropriate controls

When validating CCR8 expression, researchers should be aware that its glycosylation and sulfation patterns may affect antibody binding and protein mobility in certain assays .

What post-translational modifications occur in mouse CCR8 and how do they affect function?

Mouse CCR8 undergoes several important post-translational modifications that influence its trafficking, ligand binding, and signaling capabilities. The receptor is N-glycosylated and potentially O-glycosylated, which affects its maturation and cell surface expression . Additionally, mouse CCR8 is sulfated on tyrosine residues, specifically at positions 14 and 15, which likely plays a crucial role in ligand binding affinity and specificity .

These modifications can create challenges for researchers, including anomalous migration patterns during SDS-PAGE analysis. When working with recombinant mouse CCR8, it is important to verify whether the expression system reproduces these modifications appropriately. E. coli-derived proteins will lack these modifications, while mammalian expression systems typically preserve them. To properly study CCR8 function, researchers should:

• Select expression systems that maintain physiologically relevant modifications

• Validate glycosylation status using enzymatic deglycosylation followed by Western blotting

• Consider sulfation status when designing binding studies, as desulfated receptors may show altered ligand affinities

What are the known isoforms of mouse CCR8 and how might they differ functionally?

Mouse CCR8 exists in multiple isoform variants that may possess distinct functional properties. Two potential isoforms have been documented: one exhibits a deletion of amino acids 103-163, while another shows a methionine substitution for amino acids 125-166 . These isoforms potentially represent splice variants or alternative translational products.

The functional implications of these isoforms remain incompletely characterized but may include:

• Altered ligand binding profiles and affinities

• Different signaling pathway activation patterns

• Varied cellular localization and trafficking properties

• Distinct roles in different tissue contexts

When designing experiments, researchers should consider:

• Using isoform-specific primers or antibodies for detection

• Evaluating the expression patterns of different isoforms across tissues

• Comparing functional responses between isoforms in controlled systems

• Noting which isoform is being used in recombinant protein studies

What are the primary ligands for mouse CCR8 and how can binding be assessed?

The primary endogenous ligand for mouse CCR8 is CCL1/TCA3, while viral macrophage inflammatory protein-1 (vMIP-1) also functions as an agonist . Unlike some other chemokine receptors with multiple ligands, mouse CCR8 demonstrates relatively selective binding. This ligand specificity makes it an attractive therapeutic target.

For assessing ligand binding, researchers can employ several methodologies:

• Competitive binding assays: Using radiolabeled or fluorescently labeled CCL1 to measure displacement by test compounds.

• Calcium flux assays: Measuring intracellular calcium release following receptor activation in CCR8-transfected cells.

• Chemotaxis assays: Evaluating cell migration toward CCL1 gradients as shown in case studies, where mouse pre-B cell lines expressing CCR8 demonstrated migration responses to CCL1 but not to other chemokines like CCL18 .

• Receptor internalization assays: Quantifying CCR8 surface expression reduction following ligand exposure. As demonstrated in studies, CCL1 induces CCR8 internalization, while other chemokines like CCL18 do not .

• BRET/FRET-based assays: Monitoring conformational changes in the receptor upon ligand binding.

What signaling pathways are activated by mouse CCR8 and how can they be studied?

Mouse CCR8 primarily signals through G protein-coupled receptor (GPCR) pathways following interaction with its ligands. Key pathways activated include:

• G protein signaling (particularly Gαi), leading to inhibition of adenylyl cyclase and reduction in cAMP levels

• Phospholipase C activation resulting in IP3 production and calcium mobilization

• PI3K/AKT pathway activation leading to cell survival and migration responses

• β-arrestin recruitment pathways affecting receptor desensitization and signaling

To study these pathways, researchers can employ methodological approaches including:

• G protein activation assays: Using [35S]GTPγS binding to directly measure G protein coupling

• cAMP inhibition assays: Measuring decreases in forskolin-stimulated cAMP following receptor activation

• β-arrestin recruitment assays: Utilizing BRET-based systems to monitor β-arrestin association with the activated receptor

• Calcium flux measurements: Using fluorescent indicators like Fluo-4 to detect intracellular calcium changes

• Phospho-specific Western blotting: Detecting activation of downstream kinases like ERK1/2 and AKT

• Inhibitor studies: Applying pathway-specific inhibitors to dissect signaling mechanisms

When conducting these studies, researchers should include appropriate controls and consider the impact of the cell type used, as signaling responses may vary between systems.

How is mouse CCR8 involved in tumor immunity and what models are available for study?

Mouse CCR8 plays a critical role in tumor immunology, primarily through its expression on regulatory T cells (Tregs) within the tumor microenvironment. CCR8+ Tregs contribute significantly to immunosuppression and tumor progression through:

• Inhibiting effector T cell responses against tumor cells

• Promoting an immunosuppressive tumor microenvironment

• Enhancing tumor cell evasion of immune surveillance

• Correlating with poor prognosis in various cancer types

Researchers have developed several models for studying CCR8's role in tumor immunity:

• Tumor-infiltrating regulatory T cell (TITR) mimic models: These involve culturing regulatory T cells with tumor cell-conditioned medium and activators to generate stable CCR8-expressing Treg populations that mimic those found in tumors .

• Syngeneic mouse tumor models: Anti-murine CCR8 antibodies have demonstrated preferential depletion of Treg cells in tumors and potent anti-tumor efficacy in these models .

• Humanized mouse models: These allow for studying human CCR8+ Tregs in a tumor context.

• In vitro co-culture systems: Enabling the study of interactions between CCR8+ Tregs and other immune cells or tumor cells.

The TITR mimic model has yielded important insights, showing that while CCR8 is important for chemotaxis toward CCL1, neither CCL1 stimulation nor CCR8 blockade affected the immunosuppressive function, proliferation, or survival of the TITR mimics themselves . This suggests CCR8's primary role may be in Treg recruitment rather than direct modulation of suppressive function.

How can mouse CCR8 be effectively targeted in experimental therapeutic approaches?

Targeting mouse CCR8 as a therapeutic strategy has shown promising results, particularly in cancer immunotherapy contexts. Several approaches have been developed:

• Antibody-mediated depletion: Afucosylated antibodies like the anti-CCR8 antibody RO7502175 have been designed to eliminate CCR8+ Treg cells through enhanced antibody-dependent cellular cytotoxicity (ADCC) . This approach has demonstrated selective depletion of tumor-infiltrating Tregs while largely sparing peripheral Tregs, potentially reducing systemic autoimmune side effects.

• Receptor antagonists: Small molecule or peptide antagonists that block CCL1 binding to CCR8, preventing Treg recruitment to tumors.

• Signaling inhibitors: Compounds that interfere with CCR8 downstream signaling pathways.

• Combination approaches: Pairing CCR8-targeting with checkpoint inhibitors or other immunotherapies.

For effective experimental design when targeting mouse CCR8:

• Validate target engagement: Confirm binding of therapeutic agents to CCR8 through flow cytometry or binding assays.

• Assess functional outcomes: Measure changes in Treg recruitment, activation, and suppressive function.

• Monitor tumor responses: Evaluate tumor growth, immune infiltration, and survival outcomes.

• Evaluate safety profiles: Assess potential off-target effects and autoimmune manifestations.

In preclinical studies, anti-murine CCR8 antibodies have shown promising results with preferential depletion of tumor Tregs and potent anti-tumor efficacy in syngeneic mouse models .

What expression systems are optimal for producing functional recombinant mouse CCR8?

The production of functional recombinant mouse CCR8 presents significant technical challenges due to its complex structure and post-translational modifications. Several expression systems have been used with varying degrees of success:

• Mammalian cell systems: HEK293 cells and other mammalian cell lines provide the most physiologically relevant post-translational modifications including proper glycosylation and sulfation of tyrosine residues . This is typically the preferred system for functional studies.

• Insect cell systems: These can produce properly folded GPCRs with some post-translational modifications, though glycosylation patterns differ from mammalian cells.

• E. coli: While this system offers high yields, bacterial expression lacks post-translational modifications and often requires refolding of inclusion bodies, making it less suitable for functional studies .

• Cell-free systems: In vitro transcription/translation systems can produce CCR8 but typically lack modification capabilities.

When selecting an expression system, researchers should consider:

• The intended application (structural studies vs. functional assays)

• Required post-translational modifications

• The need for fusion tags (His, GST, Fc, etc.) for purification or detection

• Expression yields and purity requirements

For most functional studies of mouse CCR8, mammalian expression systems are recommended to ensure proper receptor folding, glycosylation, and sulfation, particularly when studying ligand binding or signaling properties.

What are the key challenges in detecting and quantifying mouse CCR8 in experimental samples?

Detecting and quantifying mouse CCR8 presents several technical challenges that researchers must address for reliable results:

• Low expression levels: CCR8 is often expressed at relatively low levels even in positive cell populations, requiring sensitive detection methods.

• Post-translational modifications: The variable glycosylation and sulfation of CCR8 can affect antibody binding and protein mobility in assays .

• Antibody specificity: Ensuring antibodies recognize the correct epitopes without cross-reactivity to other chemokine receptors.

• Receptor internalization: CCR8 undergoes ligand-induced internalization, potentially complicating surface expression analysis .

• Processing artifacts: Sample preparation can alter receptor conformation or epitope accessibility.

Methodological approaches to overcome these challenges include:

For flow cytometry:

• Use validated antibodies like Alexa Fluor 750-conjugated anti-CCR8 antibodies

• Include appropriate isotype controls

• Consider fixation and permeabilization effects on epitope recognition

• Use fresh samples when possible, as freezing may affect chemokine receptor detection

For Western blotting:

• Be aware that glycosylation causes anomalous migration patterns in SDS-PAGE

• Consider deglycosylation treatments for more accurate molecular weight assessment

• Use glycosylation-insensitive antibodies when available

For mRNA quantification:

• Design primers that distinguish between potential CCR8 isoforms

• Use appropriate housekeeping genes for normalization in different tissue contexts

For tissue samples:

• Optimize fixation conditions to preserve epitope accessibility

• Use antigen retrieval techniques appropriate for membrane proteins

• Include positive and negative control tissues with known CCR8 expression

How does mouse CCR8 heterogeneity in tumor microenvironments impact experimental design and interpretation?

Recent research has revealed significant heterogeneity in CCR8 expression patterns within tumor microenvironments, presenting important considerations for experimental design and data interpretation. This heterogeneity manifests in several ways:

• Variable expression levels: CCR8 expression intensity varies considerably between different Treg populations within the same tumor.

• Co-receptor expression patterns: CCR8+ Tregs exhibit heterogeneous co-expression of other chemokine receptors like CCR4, creating diverse Treg phenotypes with potentially different functions .

• Functional diversity: Not all CCR8+ Tregs display identical suppressive mechanisms or activation states.

• Spatial distribution: CCR8+ Tregs often show non-uniform distribution within tumors, with enrichment in specific niches.

To address these complexities in experimental design:

• Single-cell approaches: Employ single-cell RNA sequencing or mass cytometry to characterize CCR8+ cell heterogeneity rather than relying solely on bulk population analyses.

• Spatial profiling: Use multiplex immunohistochemistry or imaging mass cytometry to preserve spatial information about CCR8+ cells within tumor architecture.

• Functional stratification: Develop methods to isolate and functionally characterize CCR8+ Treg subpopulations.

• Clonal analysis: Consider T cell receptor sequencing of CCR8+ Tregs to determine clonal relationships.

When interpreting results, researchers should acknowledge that targeting CCR8 may affect different subpopulations unequally, potentially explaining variability in therapeutic responses. The observation that TITR mimics show strong CCR8 expression but CCR8 blockade does not affect their immunosuppressive function highlights the importance of understanding this heterogeneity .

What recent methodological advances improve the study of mouse CCR8 pharmacology and receptor dynamics?

Several recent methodological advances have significantly enhanced our ability to study mouse CCR8 pharmacology and receptor dynamics:

• Quantitative PK/PD modeling: Advanced pharmacokinetic/pharmacodynamic modeling approaches have been developed to capture anti-CCR8 antibody dynamics, receptor occupancy, and tumor responses in mice . These models enable more precise translation between preclinical and clinical studies.

• CRISPR-engineered reporter systems: Knock-in fluorescent or luminescent tags to endogenous CCR8 allow real-time monitoring of receptor trafficking and dynamics without overexpression artifacts.

• Nanobody-based detection tools: Single-domain antibody fragments provide improved access to conformational epitopes and can be used for super-resolution imaging of CCR8 localization.

• Bioluminescence resonance energy transfer (BRET) biosensors: These enable real-time monitoring of CCR8 activation, β-arrestin recruitment, and G protein coupling in living cells with high sensitivity.

• Afucosylated antibody development: Enhanced antibody-dependent cellular cytotoxicity (ADCC) through afucosylation has improved specific targeting and depletion of CCR8+ cells, as demonstrated with antibodies like RO7502175 .

• Integrated safety assessment approaches: Comprehensive evaluation of preclinical safety, including cytokine release assays and dose-escalation studies in non-human primates, has provided better predictive value for clinical translation .

When implementing these methods, researchers should consider:

• The need for appropriate controls and validation

• Potential differences between in vitro and in vivo receptor dynamics

• Impact of the cellular context on receptor behavior

• Species differences when translating findings

These advanced approaches provide more nuanced insights into CCR8 biology than traditional methods and allow for better prediction of therapeutic outcomes when targeting this receptor.

Experimental Tools for Mouse CCR8 Research